News

The agency’s decision was made based on data from 2 phase 3 clinical trials—ADAPT-1 and ADAPT-2—which tested the safety and efficacy of avatrombopag in 435 patients.

A family medicine physician asks fellow doctors to keep operating to the highest extent of their ability and to remind themselves of the value of their license.

Fibrocell Science, Inc released interim results and progress regarding its phase 1/2 clinical trial of FCX-007 for the treatment of recessive dystrophic epidermolysis bullosa (RDEB).

The therapy is a first of the histamine H3 receptor-antagonist/inverse agonist class—working by enhancing the histaminergic neurons in the brain.

Cerenovus’ mechanical thrombectomy device is indicated for the removal of blood clots in the 8 hours following ischemic stroke.

Harmony Biosciences, LLC, announced that the FDA has granted Breakthrough Therapy and Fast Track designations to its product, pitolisant, for the treatment of excessive daytime sleepiness and cataplexy in patients with narcolepsy.

Researchers aim to prove that it’s safe for an HIV-positive patient to receive a kidney donation from an HIV-positive donor.

Lokelma is approved for the treatment of hyperkalemia, which is characterized by elevated potassium levels often associated with cardiovascular, renal, and metabolic diseases.

The FDA had issued a Class I recall of the MindFrame Capture LP device.

CGRP inhibitor therapies have shown long-term efficacy, safety, and tolerability profiles at the clinical stages — and erenumab is just the first of them to reach the market.

The first patient has been enrolled in PEDFIC-1, a phase 3 clinical trial of A4250, an ileal bile acid transporter (IBAT) inhibitor being studied for the treatment of patients with progressive familial intrahepatic cholestasis (PFIC).

The phase 1/2 trial for ABO-102 (AAV-SGSH), clinical gene therapy for the treatment of Sanfilippo syndrome type A (MPS III A) shows efficacy in trial update.

An association between antibiotic treatment in infancy and development of atopic asthma in childhood suggests an immune-mediated effect.

L. Gail Curtis, PA-C, MPAS, DFAAPA, details the use of Optimal Team Practice by the AAPA, and the role of the physician assistant in medicine.

Adolescents with ADHD were more likely to use marijuana and cigarettes at earlier ages, which increased their risk of continuing substance use into adulthood.

A longer ICU stay, recipients of piperacillin/tazobactam and having COPD were positively associated with C. difficile in trauma/surgery patients compared with medical patients.

Between 3 and 9 months post-discharge, 36.9% of those aged 76+ years were prescribed an opioid, with a 5.0% incidence of long-term opioid use.

The FDA has approved the first-in-class CGRP monoclonal antibody erenumab for the prevention of migraines in adults, based on findings from three clinical trials.

The FDA will come to a conclusion on whether to approve Epidiolex in late June and if approved, this will be the first cannabis-based product to become FDA approved.

Genetic testing for medical conditions can be controversial, especially when it concerns newborns. Alan Copperman, MD discusses why the benefits outweigh the concerns.

The 625 mg tablet Welchol was first approved for cholesterol and/or glycemic management by the FDA in 2000.

Researchers predicted that the inclusion of these additional factors—such as DME or RVO, and Medicare Advantage plan or private insurance use—would see cost savings in excess of $30 billion.

Ambient air pollution has become one of the world's greatest killers. But physicians still differ on their involvement in fighting it.

Misinformation about clinical research, mistrust between scientists and the community, and HIV-related stigma often impede efforts to find an HIV cure.

The FDA has granted Rare Pediatric Disease Designation to Myonexus Therapeutics for its MYO-101, which is an AAV-based gene therapy for the treatment of limb girdle muscular dystrophy (LGMD) type 2E.

New data shows that an increase in the burden of AF is independently associated with a higher risk of ischemic stroke and arterial thromboembolism in patients who have not received anticoagulant medication.

This is the first FDA-approved non-opioid treatment for the management of opioid withdrawal symptoms, providing a new option for patients to select treatment best suited to their needs.

All told, 41.5% of those receiving dupilumab every 2 weeks and 38% of those receiving it every 4 weeks achieved an Eczema Area and Severity Index score ≥75%, compared with 8% of those receiving placebo.

The FDA granted rare pediatric disease designation to Castle Creek Pharmaceuticals (CCP) for diacerein 1% ointment (CCP-020) for the treatment of epidermolysis bullosa simplex (EBS).

The safety and efficacy of diacerein 1% ointment is being evaluated in the DELIVERS study.